TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06819007: A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-

Sponsor: Daiichi Sankyo · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 582 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT06819007 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06819007 Rescue Dossier →